Citigroup lowered shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a neutral rating to a sell rating in a report ...

Teladoc's growth and profitability challenges continue amid rising competition. Learn why TDOC stock remains under pressure ...

Hims & Hers (NYSE: HIMS) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the ...

Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...